Refractory hypotension due to Nivolumab-induced adrenal insufficiency

Nivolumab, a new immune checkpoint inhibitor that has been found to improve outcomes for patients with some advanced cancers, is being increasingly used. Immune checkpoint inhibitors can cause immune-related adverse events, including dermatitis, enterocolitis, hepatitis and hypophysitis, but adrenal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukizawa, Yoshiaki, Kondo, Keisuke, Ichiba, Toshihisa, Naito, Hiroshi, Mizuki, Kazuhito, Masuda, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995729/
https://www.ncbi.nlm.nih.gov/pubmed/29915446
http://dx.doi.org/10.18999/nagjms.80.2.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995729/
https://www.ncbi.nlm.nih.gov/pubmed/29915446
http://dx.doi.org/10.18999/nagjms.80.2.285

Ejemplares similares